The FDA approved pembrolizumab as adjuvant therapy for adults and children aged 12 years or older with stage IIB or IIC melanoma after complete resection.
Regulatory
FDA Orphan Drug Designation Granted to ST101 for Advanced Cutaneous Melanomas
The FDA granted a fast track designation to ST101 for the treatment of advanced cutaneous melanoma in patients who have disease progression on or after anti-PD-1/anti-PD-L1 therapy.
NICE recommends monotherapy for adjuvant treatment of stage 3 melanoma
The approval follows a successful period of monitoring and patient access through the Cancer Drugs Fund.
FDA Grants Fast Track Status to UVI Plus Checkpoint Inhibition for Melanoma Subgroup
The FDA has granted a fast track designation to UV1, a universal cancer vaccine, in combination with either pembrolizumab (Keytruda) or…